Shantha Biotechnics the first Indian company to develop, manufacture and market recombinant human healthcare product in India , has opened their new cGMP compliant state of the art high speed vaccine vial filling facilityDr. J Geeta Reddy, Hon'ble Minister Major Industries, Sugar, Commerce and Export Promotion, Govt. of A.P, inagurated the facility. Sri. B. Sam Bob, IAS, Principal Secretary Department of Industries and Commerce, Govt. of AP, was the Guest of Honour. Also present during the occasion were Sri. N.K. Prasad, IAS, commissioner of for Industries, Govt. of AP and the top officials and senior management team of Shantha Biotechnics.
The new high speed vial fill and finish suite located at Shantha Biotechnics sprawling 80,000 square foot vaccine manufacturing facility in Mechal, Hyderabad, will have a capacity to fill and finish 3,00,000 vials a day. Set up at a cost of 250 million rupees the new facility is part of Shantha Biotechnics strategic expansion plans focused on servicing existing and growing market demands for its range of vaccines. Apart from Hepatitis B, DPT-Hep B and Tetanus toxoid, the vaccines under development like Human Pappiloma Virus (HPV) and Rotavirus and the soon to be launched pentavalent vaccine will be formulated and blended in this new facility. The Fill Finish facility has 3 filling lines - a High speed vial filling line, Uniject filling line and Glass pre-fill syringe line. The installed capacities are 150,000, 60,000 and 40,000 vials per day respectively.
Speaking on the occasion Varaprasad Reddy, Managing Director, Shantha Biotechnics, Said,"The newly opened facility has given us the potential to triple our vaccine filling capacity from our current level of 1,00,000 vials to 3,00,000 vials per day." He also announced “Shantha has obtained WHO-Geneva Pre-qualification for its combination of DPT+ Hepatitis-B vaccine ‘SHANTETRA’
Shantha is currently focusing its R&D efforts in the development of generic biologicals, novel therapeutic antibodies, proteins and vaccines. Shantha conducts exploratory research in the fields of Oncology, Infectious Diseases and Platform technologies. Most recently, Shantha Biotechnics announced a strategic partnership with Merieux Alliance. In association with Shantha Biotechnics, the European company, which has a strong presence in preventive medicine, aims to create global R&D hub for prophylactic vaccine research in India. Mérieux Alliance on the other hand, will have access to Shantha Biotechnics indigenous properietory research and a branded product base in recombinants.
About Shantha Biotechnics
Shantha is the pioneer in India for modern biotech products for human healthcare and its r-DNA Hepatitis B vaccine, Shanvac-B and Shantetra (combination of DPT & Hep B) are pre-qualified by WHO, Geneva for supplying to UN agencies. Shantha aims to expand its current vaccines portfolio by launching combination vaccines and new generation vaccines produced indigenously at its WHO cGMP plant near Hyderabad. Shanvac-B is exported to more than 50 countries. Other novel products developed by Shantha include Shanferon [r-DNA Human Interferon Alpha 2b] and Shanpoietin [recombinant human Erythropoietin]
* * * * * * * * *
Media Contact for Shantha Biotechnics
Sheela
enRight Media Relations
98498 09594
enright@enrightpr.com
